Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2024 2
2025 24
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial.
van den Heerik ASVM, Horeweg N, Haverkort MAD, Kuijsters N, Kommoss S, Koppe FLA, Nowee ME, Westerveld H, De Jong MAA, Frühauf F, Cnossen JS, Mens JWM, Beukema JC, Chargari C, Gillham C, Jurgenliemk-Schulz IM, Vandecasteele K, Hamann M, Kiderlen M, Staebler A, Nijman HW, Wortman BG, Asteinidou E, de Boer SM, van den Hout WB, Verhoeven-Adema KW, Nout RA, Putter H, Bosse T, Creutzberg CL. van den Heerik ASVM, et al. Lancet Oncol. 2026 Jan;27(1):23-35. doi: 10.1016/S1470-2045(25)00612-6. Lancet Oncol. 2026. PMID: 41449145 Clinical Trial.
Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial.
Noaiseh G, Sivils KL, Campbell K, Idokogi J, Lo KH, Liva SG, Leu JH, Dhatt H, Ma K, Leonardo S, Li H, Hubbard JJ, Gottenberg JE. Noaiseh G, et al. Lancet. 2025 Nov 22;406(10518):2435-2448. doi: 10.1016/S0140-6736(25)01430-8. Epub 2025 Oct 24. Lancet. 2025. PMID: 41284548 Free article. Clinical Trial.
Therefore, we aimed to evaluate nipocalimab, a neonatal Fc receptor blocker that reduces circulating IgG, including autoantibodies, in patients with Sjogren's disease. ...
Therefore, we aimed to evaluate nipocalimab, a neonatal Fc receptor blocker that reduces circulating IgG, including autoantibodies, i …
sFlt-1/PlGF ratio use does not reduce hospitalisation duration in suspected preeclampsia: the PRECOG study, a multicentre randomised trial.
Sibiude J, Winer N, Morel O, Lecarpentier E, Masson D, Perrotin F, Huissoud C, Kayem G, Piver E, Rota M, Bondon JP, Buth V, Masson G, Guibourdenche J, Tsatsaris V. Sibiude J, et al. Sci Rep. 2025 Nov 10;15(1):39299. doi: 10.1038/s41598-025-23007-w. Sci Rep. 2025. PMID: 41214069 Free PMC article. Clinical Trial.
In this randomized controlled trial in women hospitalized for suspected of preeclampsia, the use of the sFlt-1/PlGF ratio at was not associated with a benefit in terms of duration of hospitalization or in maternal and neonatal outcomes....
In this randomized controlled trial in women hospitalized for suspected of preeclampsia, the use of the sFlt-1/PlGF ratio at was not associa …
Oral misoprostol versus vaginal dinoprostone for term labor induction among women requiring oxytocin before 4 cm: A secondary analysis of the STOPOXY trial.
Nkobetchou M, Ray CL, Girault A. Nkobetchou M, et al. Eur J Obstet Gynecol Reprod Biol. 2026 Jan;316:114809. doi: 10.1016/j.ejogrb.2025.114809. Epub 2025 Nov 3. Eur J Obstet Gynecol Reprod Biol. 2026. PMID: 41197231 Clinical Trial.
DESIGN: We conducted a secondary analysis of the STOPOXY randomized trial (assessing the impact of discontinuing oxytocin during active labor on neonatal morbidity). We included term labor inductions with oral misoprostol or vaginal dinoprostone. ...No significant differen …
DESIGN: We conducted a secondary analysis of the STOPOXY randomized trial (assessing the impact of discontinuing oxytocin during active labo …
Effect of prenatal multiple micronutrient supplements and medium-quantity lipid-based nutritional supplements on maternal weight gain and infant birth weight in rural Niger: a cluster-randomised trial.
Rattigan SM, Garba S, Plikaytis B, Sudfeld C, Guindo O, Soumana I, Langendorf C, Grais R, Isanaka S. Rattigan SM, et al. BMJ Glob Health. 2025 Nov 3;10(11):e021013. doi: 10.1136/bmjgh-2025-021013. BMJ Glob Health. 2025. PMID: 41184032 Free PMC article. Clinical Trial.
INTRODUCTION: The risk of adverse birth outcomes, such as low birth weight (<2500 g, LBW), is associated with poor maternal nutrition and weight gain in pregnancy and can increase the risk of infant mortality. We evaluated the effect of three prenatal nutritional supple …
INTRODUCTION: The risk of adverse birth outcomes, such as low birth weight (<2500 g, LBW), is associated with poor maternal nutrition and …
Sensing ultrasound localization microscopy for ultrastructural and functional imaging of neonatal kidneys.
Grieshaber-Bouyer Mandelbaum H, Wachter F, Denis L, Reisinger C, Buehler A, Yan J, Hilger AC, Jobst-Schwan T, Hebert S, Morhart P, Jüngert J, Couture O, Schiffer M, Woelfle J, Reutter H, Knieling F, Hanslik G, Regensburger AP. Grieshaber-Bouyer Mandelbaum H, et al. Ultraschall Med. 2025 Oct 23. doi: 10.1055/a-2700-9184. Online ahead of print. Ultraschall Med. 2025. PMID: 41130267 Clinical Trial. English.
This technical development aims to enable the visualization of glomeruli in the renal cortex of neonates serving as a potential imaging biopsy.This technical report describes the first use of sULM in the human neonatal kidney. Neonatal subjects were examined …
This technical development aims to enable the visualization of glomeruli in the renal cortex of neonates serving as a potential imagi …
Effect of BL23 Acupressure on Pain Among Primiparous Women During the First Stage of Labor: A Randomized, Sham-Controlled Trial.
Pishva F, Heshmat R, Sedigh Mobarakabadi S. Pishva F, et al. Pain Res Manag. 2025 Aug 20;2025:4486038. doi: 10.1155/prm/4486038. eCollection 2025. Pain Res Manag. 2025. PMID: 40880842 Free PMC article. Clinical Trial.
Twenty minutes of pressure on BL23 points at different dilatation stages were equally effective in reducing pain (p=0.13). No adverse effects on maternal and neonatal outcomes were observed in the BL23 acupressure group compared to the other groups (p > 0.05). ...
Twenty minutes of pressure on BL23 points at different dilatation stages were equally effective in reducing pain (p=0.13). No adverse effect …
Effect of the score predicting imminent delivery on the management of unexpected out-of-hospital obstetrical deliveries: a cluster randomized clinical trial.
Ricard-Hibon A, Brenckmann V, Gorlicki J, Soulat L, Bagou G, Pradeau C, Louvet F, Arnaud E, Combes X, Weinzorn E, Lecarpentier E, Joly R, Goddet S, Martin C, Jacob L, Roupioz T, Vergne M, Abensur Vuillaume L, Duchanois C, Amalric JM, Alfaiate T, Biard L, Adnet F. Ricard-Hibon A, et al. Eur J Emerg Med. 2025 Oct 1;32(5):335-343. doi: 10.1097/MEJ.0000000000001264. Epub 2024 Aug 4. Eur J Emerg Med. 2025. PMID: 40772434 Free PMC article. Clinical Trial.
The secondary endpoints included the prehospital deliveries rate without the presence of a mobile ICU team on site, call duration, satisfaction score, and maternal and neonatal mortality. MAIN RESULTS: A total of 7782 pregnant women were included in the intention-to-treat …
The secondary endpoints included the prehospital deliveries rate without the presence of a mobile ICU team on site, call duration, satisfact …
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.
Konstantinopoulos PA, Kim JW, Freyer G, Lee JY, Gaba L, Grisham RN, Colombo N, Wu X, Sehouli J, Cruz F, Cibula D, Monk BJ, Nyvang GB, Friedlander M, Lorusso D, Van Nieuwenhuysen E, Malik R, Glasspool R, Marth C, Leary A, Cortés-Salgado A, Zamagni C, Marmé F, Sufliarsky J, Hinson P, Zuradelli M, Wang C, Su F, Paule I, Miller M, Matulonis UA, González-Martín A. Konstantinopoulos PA, et al. J Clin Oncol. 2025 Sep 10;43(26):2908-2917. doi: 10.1200/JCO-25-00225. Epub 2025 Jul 23. J Clin Oncol. 2025. PMID: 40700681 Free article. Clinical Trial.
Inhaled isoflurane for sedation of mechanically ventilated children in intensive care (IsoCOMFORT): a multicentre, randomised, active-control, assessor-masked, non-inferiority phase 3 trial.
Miatello J, Palacios-Cuesta A, Radell P, Oberthuer A, Playfor S, Amores-Hernández I, Barreault S, Biedermann R, Charlo Molina MT, Encarnación Martínez J, Kuehne B, Mencía S, Méndez MD, Menzel C, Morin L, Oviedo L, Piloquet JE, Falkenhav M, Sackey P, Trieschmann U, Tissieres P; IsoCOMFORT Study Group. Miatello J, et al. Lancet Respir Med. 2025 Oct;13(10):897-910. doi: 10.1016/S2213-2600(25)00203-6. Epub 2025 Jul 15. Lancet Respir Med. 2025. PMID: 40680761 Free article. Clinical Trial.
Prophylactic hydrocortisone and the risk of sepsis in neonates born extremely preterm.
Baud O, Lehert P; PREMILOC study group. Baud O, et al. Eur J Pediatr. 2025 Jun 14;184(7):419. doi: 10.1007/s00431-025-06248-9. Eur J Pediatr. 2025. PMID: 40515786 Clinical Trial.
However, an increased risk of late-onset sepsis (LOS) was also reported in extremely preterm neonates exposed to prophylactic HC treatment. Because its causal link remains unclear, our objective was to assess the effect of prophylactic HC exposure on LOS risk, adjusted for …
However, an increased risk of late-onset sepsis (LOS) was also reported in extremely preterm neonates exposed to prophylactic HC trea …
The Effect of Probiotics on Health in Pregnancy and Infants: A Randomized, Double-Blind, Placebo-Controlled Trial.
Binda S, Chow-Shi-Yée M, El Salti S, Auclair-Ouellet N, Oula ML, Carton T, Leuillet S, Tomassi D, Hemmings R, Kadoch IJ. Binda S, et al. Nutrients. 2025 May 28;17(11):1825. doi: 10.3390/nu17111825. Nutrients. 2025. PMID: 40507094 Free PMC article. Clinical Trial.
Background/Objectives: There is growing interest in the benefits of probiotic supplementation during pregnancy and lactation, but evidence supporting the beneficial effects for mother-infant dyads remains scarce. This study assessed the effects of probiotic supplementation …
Background/Objectives: There is growing interest in the benefits of probiotic supplementation during pregnancy and lactation, but evidence s …
Dostarlimab and niraparib in primary advanced ovarian cancer.
Hardy-Bessard AC, Pujade-Lauraine E, Moore RG, Montestruc F, Redondo A, Mirza MR, Cibula D, Ciuleanu TE, Gilbert L, Eitan R, Zagouri F, Pignata S, Glasspool R, Pfisterer J, Phaëton R, Anderson CK, Rodrigues M, Gaba L, Bakirtzi E, Fauci JM, Kalbacher E, Musa FB, Gorman S, Duska LR, Gladieff L, Braly P, Joly F, Thomes Pepin J, Ray-Coquard I, Moore KN. Hardy-Bessard AC, et al. Ann Oncol. 2025 Dec;36(12):1503-1513. doi: 10.1016/j.annonc.2025.05.009. Epub 2025 Jun 2. Ann Oncol. 2025. PMID: 40461381 Free article. Clinical Trial.
180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial.
Munro APS, Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, Kaiser F, Cohen R, Pinquier D, Vassilouthis NC, Carreno M, Moreau C, Bourron P, Marcelon L, Mari K, Roberts M, Tissières P, Royal S, Faust SN; HARMONIE Study Group. Munro APS, et al. Lancet Child Adolesc Health. 2025 Jun;9(6):404-412. doi: 10.1016/S2352-4642(25)00102-6. Lancet Child Adolesc Health. 2025. PMID: 40379431 Free article. Clinical Trial.
The primary analyses of HARMONIE showed that nirsevimab reduced infant hospitalisations due to RSV-associated lower respiratory tract infection through the RSV season. ...This finding provides global health systems greater flexibility when implementing nirsevimab, providin …
The primary analyses of HARMONIE showed that nirsevimab reduced infant hospitalisations due to RSV-associated lower respiratory tract …
Minimally invasive simple hysterectomy in low-risk cervical cancer: a single-arm trial with stopping rules (ENGOT-cx23/MITO/LASH trial).
Bizzarri N, Querleu D, Ramirez PT, Plante M, Giannarelli D, Falconer H, Abu-Rustum NR, Cibula D, Martinez A, Laas E, Fotopoulou C, Chiva L, Pavone M, Pedone Anchora L, Fanfani F, Fagotti A, Scambia G. Bizzarri N, et al. Int J Gynecol Cancer. 2025 Jun;35(6):101818. doi: 10.1016/j.ijgc.2025.101818. Epub 2025 Apr 5. Int J Gynecol Cancer. 2025. PMID: 40328196 Free PMC article. Clinical Trial.
ADAPT NXT: Fixed Cycles or Every-Other-Week IV Efgartigimod in Generalized Myasthenia Gravis.
Habib AA, Claeys KG, Bril V, Hussain Y, Gwathmey K, Sahagian G, Cortés-Vicente E, Brauer E, Gelinas D, Sumbul A, Jimenez RH, Hristova D, Masschaele D, Mantegazza R, Meisel A, Attarian S; ADAPT NXT Study Group. Habib AA, et al. Ann Clin Transl Neurol. 2025 Jun;12(6):1162-1170. doi: 10.1002/acn3.70051. Epub 2025 Apr 14. Ann Clin Transl Neurol. 2025. PMID: 40223516 Free PMC article. Clinical Trial.
Testosterone Effects on Short-term Physical, Hormonal, and Neurodevelopmental Outcomes (TESTO) in Infants With 47,XXY.
Davis SM, Howell S, Janusz J, Lahlou N, Reynolds R, Thompson T, Swenson K, Wilson R, Ross JL, Zeitler PS, Tartaglia NR. Davis SM, et al. J Clin Endocrinol Metab. 2025 Nov 18;110(12):3493-3504. doi: 10.1210/clinem/dgaf217. J Clin Endocrinol Metab. 2025. PMID: 40177735 Clinical Trial.
MAIN OUTCOME MEASURES: The a priori primary outcomes were change in percent fat mass z-scores and change in the total composite percentile on Alberta Infant Motor Scales assessment from baseline to 12 weeks. RESULTS: The between-group difference in change in percent fat ma …
MAIN OUTCOME MEASURES: The a priori primary outcomes were change in percent fat mass z-scores and change in the total composite percentile o …
A novel human milk fortifier supports adequate growth in very low birth weight infants: a non-inferiority randomised controlled trial.
Picaud JC, Reynolds PR, Clarke P, van den Hooven E, van Weissenbruch MM, van Lingen RA, Goedhart A, Botma A, Boettger R, van Westering-Kroon E, Fusch C, Hascoet JM; RENOIR Study Group. Picaud JC, et al. Arch Dis Child Fetal Neonatal Ed. 2025 Aug 19;110(5):512-519. doi: 10.1136/archdischild-2024-327282. Arch Dis Child Fetal Neonatal Ed. 2025. PMID: 40037774 Free PMC article. Clinical Trial.
DESIGN: Double-blind, randomised controlled trial. SETTING: Nine European neonatal intensive care units. PATIENTS: HM-fed infants born at <32-week gestational age. ...No significant differences were reported in common neonatal morbidities including necrotising en …
DESIGN: Double-blind, randomised controlled trial. SETTING: Nine European neonatal intensive care units. PATIENTS: HM-fed infants bor …
Simulation-Based Echocardiography Training Enhanced Competence and Self-Confidence in Neonatal Residents.
Blanchetière A, Guillouët E, Favrais G, Lardennois C, Bellot A, Savey B. Blanchetière A, et al. Acta Paediatr. 2025 Jul;114(7):1623-1632. doi: 10.1111/apa.70003. Epub 2025 Jan 31. Acta Paediatr. 2025. PMID: 39891031 Free PMC article. Clinical Trial.
AIM: Mastering echocardiography scans is essential in neonatology, but bedside training can be difficult due to the instability of neonatal patients. ...CONCLUSION: Simulation-based training was a valuable approach for training neonatal residents to perform e …
AIM: Mastering echocardiography scans is essential in neonatology, but bedside training can be difficult due to the instability of …
Outcomes of extremely preterm infants who participated in a randomised trial of dopamine for treatment of hypotension (the HIP trial) at 2 years corrected age.
Marlow N, Barrington KJ, ODonnell CPF, Miletin J, Naulaers G, Cheung PY, Corcoran JD, El-Khuffash A, Boylan GB, Livingstone V, Pons G, Straňák Z, Van Laere D, Macko J, Wiedermannova H, Dempsey EM; HIP consortium. Marlow N, et al. Arch Dis Child Fetal Neonatal Ed. 2025 Oct 17;110(6):542-547. doi: 10.1136/archdischild-2024-327894. Arch Dis Child Fetal Neonatal Ed. 2025. PMID: 39832819 Free PMC article. Clinical Trial.
Bronchopulmonary dysplasia to predict neurodevelopmental impairment in infants born extremely preterm.
Baud O, Lehert P; PREMILOC study group. Baud O, et al. Pediatr Res. 2025 Jun;97(7):2436-2442. doi: 10.1038/s41390-024-03601-w. Epub 2024 Oct 24. Pediatr Res. 2025. PMID: 39448816 Free PMC article. Clinical Trial.
BACKGROUND: Bronchopulmonary dysplasia (BPD) in extremely low gestational age neonates (ELGANs) was associated with neurodevelopmental impairment (NDI). However, the best endpoint of BPD assessment to predict subsequent NDI remains unclear. ...
BACKGROUND: Bronchopulmonary dysplasia (BPD) in extremely low gestational age neonates (ELGANs) was associated with neurodevelopmenta …